# Symbiosis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/symbiosis

- Industry: Biotechnology
- Headquarters: Osaka, Japan
- Website: www.shinbiosis.com
- Total disclosed funding: $0.1M
- Latest round: Series A (Aug 24, 2022)
- Investors on record: 1

## About

Established in 2017 and based in Osaka, Japan, Symbiosis Co., Ltd. develops and manufactures ultra-fine bubbles and fungal fluid for intestinal flora. In August 2022, Symbiosis Co., Ltd. raised venture funding from Future Venture Capital. As of 2022, Mikiko Tanaka is the CEO of the company.

The company's business includes microorganism business (intestinal bacteria), which aims for coexistence and co-prosperity with microorganisms such as intestinal bacteria; and the NanoGAS® (UFB) business, which is a core technology as a solvent for transplanted bacteria that includes NanoGAS® validation test results and NanoGAS® application examples.

The firm also engages in the research and development of medical treatments for diseases such as autism spectrum disorders, ulcerative colitis, and renal diseases, as well as working to develop the technique of intestinal flora transplantation and utilize nanobubble technology.

## Funding rounds

- Series A, Aug 24, 2022, $0.1M — MIRAIDOOR

## Investors

- MIRAIDOOR (https://capitalatlas.ai/funds/miraidoor) — Series A